Oxitec CEO To Testify Before Congressional Committee On May 25th
OXFORD, England, May 23, 2016 /PRNewswire/ --
Oxitec CEO Hadyn Parry will testify on Wednesday, May 25th at 10:15 a.m. ET before the United States House Committee on Science, Space and Technology about the role genetically engineered mosquitos can play in controlling the spread of the Aedes aegypti mosquito, a known carrier of the Zika virus.
(Logo: http://photos.prnewswire.com/prnh/20150630/227348 )
Oxitec has pioneered a genetically engineered male mosquito with a self-limiting gene. Trials in Brazil, Panama and the Cayman Islands have demonstrated that Oxitec's technology produces an unparalleled reduction in the population of the dangerous Aedes aegypti mosquito. The Food & Drug Administration recently concluded a public comment period after issuing a preliminary finding of no significant impact in support of a field study of Oxitec's solution in Key Haven, Fla.
WHO: Hadyn Parry, CEO, Oxitec, Ltd.
WHAT: Testifying before the U.S. House Committee on Science, Space and Technology about the role an Oxitec engineered male mosquito can play in controling the spread of the Aedes aegypti mosquito, a known carrier of the Zika virus.
WHEN: Wednesday, May 25, 2016 at 10:15 a.m. ET
WHERE: 2318 Rayburn House Office Building, Washington, DC.
About Oxitec
Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world's biggest problems.
Press contact:
Oxitec:
Matt Warren
info@oxitec.com
+44(0)-1235-832393
For more information:
Site: http://www.oxitec.com
Facebook: http://www.facebook.com/oxitec
Twitter: http://www.twitter.com/oxitec
Oxitec CEO Hadyn Parry will testify on Wednesday, May 25th at 10:15 a.m. ET before the United States House Committee on Science, Space and Technology about the role genetically engineered mosquitos can play in controlling the spread of the Aedes aegypti mosquito, a known carrier of the Zika virus.
(Logo: http://photos.prnewswire.com/prnh/20150630/227348 )
Oxitec has pioneered a genetically engineered male mosquito with a self-limiting gene. Trials in Brazil, Panama and the Cayman Islands have demonstrated that Oxitec's technology produces an unparalleled reduction in the population of the dangerous Aedes aegypti mosquito. The Food & Drug Administration recently concluded a public comment period after issuing a preliminary finding of no significant impact in support of a field study of Oxitec's solution in Key Haven, Fla.
WHO: Hadyn Parry, CEO, Oxitec, Ltd.
WHAT: Testifying before the U.S. House Committee on Science, Space and Technology about the role an Oxitec engineered male mosquito can play in controling the spread of the Aedes aegypti mosquito, a known carrier of the Zika virus.
WHEN: Wednesday, May 25, 2016 at 10:15 a.m. ET
WHERE: 2318 Rayburn House Office Building, Washington, DC.
About Oxitec
Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK). Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world's biggest problems.
Press contact:
Oxitec:
Matt Warren
info@oxitec.com
+44(0)-1235-832393
For more information:
Site: http://www.oxitec.com
Facebook: http://www.facebook.com/oxitec
Twitter: http://www.twitter.com/oxitec